Tcr2 Therapeutics (NASDAQ:TCRR) Raised to “Buy” at Zacks Investment Research

Tcr2 Therapeutics (NASDAQ:TCRR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, reports. The brokerage currently has a $18.00 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 13.56% from the stock’s current price.

According to Zacks, “TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts. “

A number of other brokerages also recently issued reports on TCRR. ValuEngine raised Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Roth Capital assumed coverage on Tcr2 Therapeutics in a research note on Friday, May 31st. They issued a “neutral” rating and a $16.00 target price for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.17.

Shares of TCRR traded down $1.19 during midday trading on Thursday, reaching $15.85. The company had a trading volume of 9,999 shares, compared to its average volume of 107,213. Tcr2 Therapeutics has a 1-year low of $10.04 and a 1-year high of $25.47. The company has a market capitalization of $409.08 million and a PE ratio of -0.16. The business has a 50 day simple moving average of $14.35.

Tcr2 Therapeutics (NASDAQ:TCRR) last issued its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.11. As a group, equities research analysts expect that Tcr2 Therapeutics will post -5.66 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. EcoR1 Capital LLC acquired a new stake in shares of Tcr2 Therapeutics during the 2nd quarter worth about $231,000. Charles Schwab Investment Management Inc. acquired a new position in Tcr2 Therapeutics in the 2nd quarter valued at about $349,000. Laurion Capital Management LP acquired a new position in Tcr2 Therapeutics in the 1st quarter valued at about $417,000. Parametric Portfolio Associates LLC grew its position in Tcr2 Therapeutics by 23.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock valued at $501,000 after acquiring an additional 6,672 shares in the last quarter. Finally, Dean Capital Investments Management LLC acquired a new position in Tcr2 Therapeutics in the 1st quarter valued at about $694,000. 33.45% of the stock is owned by hedge funds and other institutional investors.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Recommended Story: What does the Producer Price Index (PPI) tell investors?

Get a free copy of the Zacks research report on Tcr2 Therapeutics (TCRR)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with's FREE daily email newsletter.